The immune system and hormone-receptor positive breast cancer: Is it really a dead end?

Cancer Treatment Reviews

Volumn 46, Issue , 2016, Pages 9-19

  Dieci, Maria Vittoria ^a,b   Griguolo, Gaia ^a,b   Miglietta, Federica ^b   Guarneri, Valentina ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Breast cancer; Endocrine therapy; Estrogen receptor; Immune checkpoints; Immunity; Tumor infiltrating lymphocytes

Indexed keywords

AROMATASE INHIBITOR; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOOXYGENASE 2; GAMMA INTERFERON; HORMONE RECEPTOR; INTERLEUKIN 12; PEMBROLIZUMAB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TICILIMUMAB; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VORINOSTAT; ESTROGEN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CELL INTERACTION; DENDRITIC CELL; GENE EXPRESSION; HORMONE POSITIVE BREAST CANCER; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; NATURAL KILLER CELL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; BREAST TUMOR; CARCINOGENESIS; FEMALE; IMMUNOLOGY; INFLAMMATORY BREAST CANCER; METABOLISM;

BREAST NEOPLASMS; CARCINOGENESIS; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; RECEPTORS, ESTROGEN;

EID: 84964509983     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.03.011     Document Type: Review

References (100)

1. Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Van Eenoo F., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013, 31:860-867.
2. Loi S., Michiels S., Salgado R., Sirtaine N., Jose V., Fumagalli D., et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014, 25:1544-1550.
3. Liu S., Lachapelle J., Leung S., Gao D., Foulkes W.D., Nielsen T.O. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 2012, 14:R48.
4. Adams S., Gray R.J., Demaria S., Goldstein L., Perez E.A., Shulman L.N., et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014, 32:2959-2966.
5. Dieci M.V., Mathieu M.C., Guarneri V., Conte P., Delaloge S., Andre F., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol 2015, 26:1698-1704.
6. Denkert C., Loibl S., Noske A., Roller M., Muller B.M., Komor M., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010, 28:105-113.
7. Denkert C., von Minckwitz G., Brase J.C., Sinn B.V., Gade S., Kronenwett R., et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015, 33:983-991.
8. Ibrahim E.M., Al-Foheidi M.E., Al-Mansour M.M., Kazkaz G.A. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat 2014, 148:467-476.
9. Loi S., Drubay D., Adams S., Francis P.A., Joensuu H., Dieci M.V., et al. Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy. 2015 San Antonio Breast Cancer Symposium 2015, S1-03.
10. Molinero L., Yu J., Li C., Deurloo R., Dent R.A., Bell R., et al. Analysis of molecular prognostic factors associated with tumor immune and stromal microenvironment in BEATRICE, an open-label phase 3 trial in early triple-negative breast cancer (eTNBC). 2015 San Antonio Breast Cancer Symposium 2015, S1-01.
11. Kotoula V., Chatzopoulos K., Lakis S., Alexopoulou Z., Timotheadou E., Zagouri F., et al. Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget 2015.
12. Bianchini G., Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 2014, 15:e58-68.
13. Jiang X., Shapiro D.J. The immune system and inflammation in breast cancer. Mol Cell Endocrinol 2014, 382:673-682.
14. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
15. Salgado R., Denkert C., Demaria S., Sirtaine N., Klauschen F., Pruneri G., et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015, 26:259-271.
16. Ruffell B., Au A., Rugo H.S., Esserman L.J., Hwang E.S., Coussens L.M. Leukocyte composition of human breast cancer. Proc Natl Acad Sci USA 2012, 109:2796-2801.
17. Baumgarten S.C., Frasor J. Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol 2012, 26:360-371.
18. Lee Y.J., Han Y., Lu H.T., Nguyen V., Qin H., Howe P.H., et al. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol 1997, 158:2065-2075.
19. Jinushi M., Komohara Y. Tumor-associated macrophages as an emerging target against tumors: creating a new path from bench to bedside. Biochim Biophys Acta 2015, 1855:123-130.
20. Bruunsgaard H., Pedersen M., Pedersen B.K. Aging and proinflammatory cytokines. Curr Opin Hematol 2001, 8:131-136.
21. Cleary M.P., Grossmann M.E. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 2009, 150:2537-2542.
22. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 2006, 6:281-291.
23. Huang Z., Hankinson S.E., Colditz G.A., Stampfer M.J., Hunter D.J., Manson J.E., et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997, 278:1407-1411.
24. Reeves G.K., Pirie K., Beral V., Green J., Spencer E., Bull D., et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007, 335:1134.
25. Key T.J., Appleby P.N., Reeves G.K., Roddam A., Dorgan J.F., Longcope C., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003, 95:1218-1226.
26. Howe L.R., Subbaramaiah K., Hudis C.A., Dannenberg A.J. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res 2013, 19:6074-6083.
27. Bowers L.W., Maximo I.X., Brenner A.J., Beeram M., Hursting S.D., Price R.S., et al. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions. Cancer Res 2014, 74:4446-4457.
28. Terry M.B., Gammon M.D., Zhang F.F., Tawfik H., Teitelbaum S.L., Britton J.A., et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004, 291:2433-2440.
29. Irahara N., Miyoshi Y., Taguchi T., Tamaki Y., Noguchi S. Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer. Int J Cancer 2006, 118:1915-1921.
30. Madeddu C., Gramignano G., Floris C., Murenu G., Sollai G., Maccio A. Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer. J Cell Mol Med 2014, 18:2519-2529.
31. Subbaramaiah K., Morris P.G., Zhou X.K., Morrow M., Du B., Giri D., et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discovery 2012, 2:356-365.
32. Sullivan N.J., Sasser A.K., Axel A.E., Vesuna F., Raman V., Ramirez N., et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947.
33. Sasser A.K., Sullivan N.J., Studebaker A.W., Hendey L.F., Axel A.E., Hall B.M. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J 2007, 21:3763-3770.
34. Studebaker A.W., Storci G., Werbeck J.L., Sansone P., Sasser A.K., Tavolari S., et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008, 68:9087-9095.
35. Zhang Q., Qin J., Zhong L., Gong L., Zhang B., Zhang Y., et al. CCL5-mediated Th2 immune polarization promotes metastasis in luminal breast cancer. Cancer Res 2015, 75:4312-4321.
36. Arteaga C.L., Koli K.M., Dugger T.C., Clarke R. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst 1999, 91:46-53.
37. Taylor M.A., Lee Y.H., Schiemann W.P. Role of TGF-beta and the tumor microenvironment during mammary tumorigenesis. Gene Expr 2011, 15:117-132.
38. Tian M., Neil J.R., Schiemann W.P. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011, 23:951-962.
39. Cohen E.N., Gao H., Anfossi S., Mego M., Reddy N.G., Debeb B., et al. Inflammation mediated metastasis: immune induced epithelial-to-mesenchymal transition in inflammatory breast cancer cells. PLoS One 2015, 10:e0132710.
40. Elgert K.D., Alleva D.G., Mullins D.W. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998, 64:275-290.
41. Yin Y., Chen X., Shu Y. Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells. Biomed Pharmacother 2009, 63:421-428.
42. Jeoung D.I., Tang B., Sonenberg M. Effects of tumor necrosis factor-alpha on antimitogenicity and cell cycle-related proteins in MCF-7 cells. J Biol Chem 1995, 270:18367-18373.
43. To S.Q., Cheung V., Lazarus K.A., Knower K.C., Clyne C.D. Estradiol regulates tumor necrosis factor-alpha expression and secretion in estrogen receptor positive breast cancer cells. Mol Cell Endocrinol 2014, 394:21-28.
44. Nagari A., Franco H.L. Interplay between inflammatory and estrogen signaling in breast cancer. Cytokine 2015, 76:588-590.
45. Murray J.I., West N.R., Murphy L.C., Watson P.H. Intratumoural inflammation and endocrine resistance in breast cancer. Endocr Relat Cancer 2015, 22:R51-R67.
46. Quaedackers M.E., van den Brink C.E., van der Saag P.T., Tertoolen L.G. Direct interaction between estrogen receptor alpha and NF-kappaB in the nucleus of living cells. Mol Cell Endocrinol 2007, 273:42-50.
47. Prieto G.A., Rosenstein Y. Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology 2006, 118:58-65.
48. Polanczyk M.J., Hopke C., Vandenbark A.A., Offner H. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 2006, 84:370-378.
49. Mostafa A.A., Codner D., Hirasawa K., Komatsu Y., Young M.N., Steimle V., et al. Activation of ERalpha signaling differentially modulates IFN-gamma induced HLA-class II expression in breast cancer cells. PLoS One 2014, 9:e87377.
50. Hagemann T., Wilson J., Kulbe H., Li N.F., Leinster D.A., Charles K., et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005, 175:1197-1205.
51. Hollmen M., Roudnicky F., Karaman S., Detmar M. Characterization of macrophage-cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Sci Rep 2015, 5:9188.
52. Nalbandian G., Paharkova-Vatchkova V., Mao A., Nale S., Kovats S. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol 2005, 175:2666-2675.
53. Komi J., Lassila O. Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells. Blood 2000, 95:2875-2882.
54. Bebo B.F., Dehghani B., Foster S., Kurniawan A., Lopez F.J., Sherman L.S. Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia 2009, 57:777-790.
55. de Kozak Y., Andrieux K., Villarroya H., Klein C., Thillaye-Goldenberg B., Naud M.C., et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 2004, 34:3702-3712.
56. Behjati S., Frank M.H. The effects of tamoxifen on immunity. Curr Med Chem 2009, 16:3076-3080.
57. Li B., Li Y., Wang X.Y., Yan Z.Q., Liu H., Liu G.R., et al. Profile of differentially expressed intratumoral cytokines to predict the immune-polarizing side effects of tamoxifen in breast cancer treatment. Am J Cancer Res 2015, 5:726-737.
58. Svensson S., Abrahamsson A., Rodriguez G.V., Olsson A.K., Jensen L., Cao Y., et al. CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer. Clin Cancer Res 2015, 21:3794-3805.
59. Joffroy C.M., Buck M.B., Stope M.B., Popp S.L., Pfizenmaier K., Knabbe C. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res 2010, 70:1314-1322.
60. Wang J., Zhang Q., Jin S., Feng M., Kang X., Zhao S., et al. Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis. Exp Gerontol 2009, 44:398-405.
61. Chan M.S., Wang L., Felizola S.J., Ueno T., Toi M., Loo W., et al. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients-an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. Int J Biol Markers 2012, 27:e295-e304.
62. Generali D., Bates G., Berruti A., Brizzi M.P., Campo L., Bonardi S., et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 2009, 15:1046-1051.
63. Ali H.R., Provenzano E., Dawson S.J., Blows F.M., Liu B., Shah M., et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 2014, 25:1536-1543.
64. Bates G.J., Fox S.B., Han C., Leek R.D., Garcia J.F., Harris A.L., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006, 24:5373-5380.
65. Liu S., Foulkes W.D., Leung S., Gao D., Lau S., Kos Z., et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 2014, 16:432. 014-0432-8.
66. Engels C.C., Charehbili A., van de Velde C.J., Bastiaannet E., Sajet A., Putter H., et al. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat 2015, 149:587-596.
67. Blok E., Engels C.C., Jongste E., Dekker-Ensink G., Kroep J.R., Kuppen P.J.K., et al. Tumour immune subtyping as a predictive biomarker for adjuvant endocrine therapy in early breast cancer. 2015 San Antonio Breast Cancer Symposium 2015, P3-07-35.
68. Issa-Nummer Y., Darb-Esfahani S., Loibl S., Kunz G., Nekljudova V., Schrader I., et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant GeparQuinto trial. PLoS One 2013, 8:e79775.
69. Dieci M.V., Ficarra G., Conte P.F., Guarneri V. Tumor infiltrating lymphocytes and Ki67 suppression after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. J Clin Oncol 2015, 33(Suppl. abstr 562).
70. Guarneri V., Frassoldati A., Ficarra G., Puglisi F., Andreetta C., Michelotti A., et al. Phase II, randomized trial of preoperative epirubicin-paclitaxel+/- gefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Res Treat 2008, 110:127-134.
71. Dunbier A.K., Ghazoui Z., Anderson H., Salter J., Nerurkar A., Osin P., et al. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Res 2013, 19:2775-2786.
72. Guarneri V., Generali D.G., Frassoldati A., Artioli F., Boni C., Cavanna L., et al. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. J Clin Oncol 2014, 32:1050-1057.
73. Filipits M., Rudas M., Jakesz R., Dubsky P., Fitzal F., Singer C.F., et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011, 17:6012-6020.
74. Zhang Y., Schnabel C.A., Schroeder B.E., Jerevall P.L., Jankowitz R.C., Fornander T., et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 2013, 19:4196-4205.
75. Desmedt C., Haibe-Kains B., Wirapati P., Buyse M., Larsimont D., Bontempi G., et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165.
76. Ignatiadis M., Singhal S.K., Desmedt C., Haibe-Kains B., Criscitiello C., Andre F., et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012, 30:1996-2004.
77. Gao Q., Patani N., Dunbier A.K., Ghazoui Z., Zvelebil M., Martin L.A., et al. Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response. Clin Cancer Res 2014, 20:2485-2494.
78. Iwamoto T., Bianchini G., Booser D., Qi Y., Coutant C., Shiang C.Y., et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 2011, 103:264-272.
79. Vendrell J.A., Robertson K.E., Ravel P., Bray S.E., Bajard A., Purdie C.A., et al. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res 2008, 10:R88.
80. Chanrion M., Negre V., Fontaine H., Salvetat N., Bibeau F., Mac Grogan G., et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008, 14:1744-1752.
81. Jansen M.P., Foekens J.A., van Staveren I.L., Dirkzwager-Kiel M.M., Ritstier K., Look M.P., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005, 23:732-740.
82. Turnbull A.K., Arthur L.M., Renshaw L., Larionov A.A., Kay C., Dunbier A.K., et al. Accurate prediction and validation of response to endocrine therapy in breast cancer. J Clin Oncol 2015, 33:2270-2278.
83. Ribas R., Ghazoui Z., Gao Q., Pancholi S., Rani A., Dunbier A., et al. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers. Breast Cancer Res 2014, 16:447. [014-0447-1].
84. Bianchini G., Qi Y., Alvarez R.H., Iwamoto T., Coutant C., Ibrahim N.K., et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010, 28:4316-4323.
85. Bianchini G., Lajos P., Yuan Q., Takayuki I., Catherine M.K., Milvia Z., et al. A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer. J Clin Oncol 2012, 30(Suppl. abstr 545).
86. Emens L.A., Braiteh F.S., Cassier P., DeLord J., Eder J.P., Shen X., et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Res 2015, 75. AACR, Philadelphia (PA), [Suppl. 9: Abstract nr PD1-6].
87. Nanda R., Chow L.Q., Dees E.C. A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res 2015, 75. AACR, Philadelphia (PA), [Suppl. 9: Abstract nr S1-09].
88. Brignone C., Gutierrez M., Mefti F., Brain E., Jarcau R., Cvitkovic F. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010, 8:71. [5876-8-71].
89. Basu G.D., Ghazalpour A., Vader R., Reddy S., Anderson K., McCullough A., et al. Expression of novel immunotherapeutic targets in luminal breast cancer patients. Cancer Res 2015, 75. AACR, Philadelphia (PA), [Suppl. 9: Abstract nr P5-04-08].
90. Sabatier R., Finetti P., Mamessier E., Adelaide J., Chaffanet M., Ali H.R., et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 2015, 6:5449-5464.
91. Vonderheide R.H., LoRusso P.M., Khalil M., Gartner E.M., Khaira D., Soulieres D., et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 2010, 16:3485-3494.
92. Savas P., Caramia F., Teo Z.L., Loi S. Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene. Curr Opin Oncol 2014, 26:562-567.
93. Stagg J., Loi S., Divisekera U., Ngiow S.F., Duret H., Yagita H., et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 2011, 108:7142-7147.
94. Park S., Jiang Z., Mortenson E.D., Deng L., Radkevich-Brown O., Yang X., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160-170.
95. Perez-Hernandez A.I., Catalan V., Gomez-Ambrosi J., Rodriguez A., Fruhbeck G. Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol (Lausanne) 2014, 5:65.
96. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11:85-97.
97. Loi S., Dushyanthen S., Beavis P.A., Salgado R., Denkert C., Savas P., et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 2015, [ahead of print].
98. Mahmoud S.M., Lee A.H., Paish E.C., Macmillan R.D., Ellis I.O., Green A.R. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 2012, 132:545-553.
99. Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Lee A.H., Ellis I.O., et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 2011, 127:99-108.
100. Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Grainge M.J., Lee A.H., et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29:1949-1955.